» Articles » PMID: 22995937

Transport of PEGylated Liposomes from the Splenic Marginal Zone to the Follicle in the Induction Phase of the Accelerated Blood Clearance Phenomenon

Overview
Journal Immunobiology
Publisher Elsevier
Date 2012 Sep 22
PMID 22995937
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The accelerated blood clearance (ABC) phenomenon has been reported to enhance the clearance of PEGylated liposomes from the blood circulation when the liposomes are injected into the same animal repeatedly. We have shown that anti-PEG IgM production from splenic B cells is crucial in the ABC phenomenon. In this study, we describe the crucial role of marginal zone (MZ) B cells in the anti-PEG IgM production and recognition of PEGylated liposomes in the induction phase of ABC phenomenon. Suppression of the anti-PEG IgM production was correlated with the disappearance of IgM(high) cells in the MZ, particularly MZ-B cells, following cyclophosphamide (CPA)-treatment, confirming that splenic MZ-B cells are responsible for anti-PEG IgM production. The MZ-B cells stimulated by a first dose of PEGylated liposomes internalized the second dose of PEGylated liposomes in a PEG modification-dependent manner and transported the liposomes into the follicle (FO) region. To the best of our knowledge, this is the first report showing that PEGylated liposome is recognized by MZ-B cells and transported to the FO region like blood-borne antigens or immune complexes. It is likely that PEGylated liposomes are recognized as a TI-2 antigen by the first line of defense against life-threatening infections by blood-borne organisms. Our study may have implications for immunogenicity of synthesized polymer-grafted therapeutics including nanocarriers, nucleic acids and proteins.

Citing Articles

Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d.

Chaudhary N, Kasiewicz L, Newby A, Arral M, Yerneni S, Melamed J Nat Biomed Eng. 2024; 8(11):1483-1498.

PMID: 39363106 PMC: 11863198. DOI: 10.1038/s41551-024-01256-w.


Reexamining the effects of drug loading on the in vivo performance of PEGylated liposomal doxorubicin.

Yu Y, Wu E, Lin S, Chu Y, Yang Y, Pan F Acta Pharmacol Sin. 2023; 45(3):646-659.

PMID: 37845342 PMC: 10834505. DOI: 10.1038/s41401-023-01169-5.


Cell-targeted vaccines: implications for adaptive immunity.

Ung T, Rutledge N, Weiss A, Esser-Kahn A, Deak P Front Immunol. 2023; 14:1221008.

PMID: 37662903 PMC: 10468591. DOI: 10.3389/fimmu.2023.1221008.


Studying how administration route and dose regulates antibody generation against LNPs for mRNA delivery with single-particle resolution.

Munter R, Christensen E, Andresen T, Larsen J Mol Ther Methods Clin Dev. 2023; 29:450-459.

PMID: 37251983 PMC: 10220314. DOI: 10.1016/j.omtm.2023.05.008.


Covid-19 vaccines elicit effective IgG responses in an elderly thymus cancer patient with chemotherapy.

Koller A, Szebeni J Hum Vaccin Immunother. 2023; 19(1):2188035.

PMID: 37062957 PMC: 10114996. DOI: 10.1080/21645515.2023.2188035.